SEARCH

SEARCH BY CITATION

References

  • 1
    A.P.A. Diagnostic and statistical manual of mental disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000, pp. 785787.
  • 2
    Wonderlich SA,Gordon KH,Mitchell JE,Crosby RD,Engel SG. The validity and clinical utility of binge eating disorder. Int JEat Disord 2009; 42: 687705.
  • 3
    A.P.A. DSM-V Development Eating Disorders, 2010. Available at: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision. aspx?rid=372#.
  • 4
    Hudson JI,Hiripi E,Pope HGJr,Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 61: 348358.
  • 5
    Pope HGJr,Lalonde JK,Pindyck LJ,Walsh T,Bulik CM,Crow SJ, et al. Binge eating disorder: A stable syndrome. Am J Psychiatry 2006; 163: 21812183.
  • 6
    Javaras KN,Pope HG,Lalonde JK,Roberts JL,Nillni YI,Laird NM, et al. Co-occurrence of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 2008; 69: 266273.
  • 7
    Fichter MM,Quadflieg N,Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: Relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41: 577586.
  • 8
    Grilo CM,White MA,Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord 2009; 42: 228234.
  • 9
    Peterson CB,Miller KB,Crow SJ,Thuras P,Mitchell JE. Subtypes of binge eating disorder based on psychiatric history. Int J Eat Disord 2005; 38: 273276.
  • 10
    McElroy S,Guerdjikova A,O'Melia A. The oxford handbook of eating disorders: Pharmacotherapy of the eating disorders. New York, NY: Oxford University Press, 2010, pp. 417451.
  • 11
    Gartlehner G,Thaler K,Hansen RA,Gaynes BN. The general and comparative efficacy and safety of duloxetine in major depressive disorder: A systematic review and meta-analysis. Drug Saf 2009; 32: 11591173.
  • 12
    Leombruni P,Lavagnino L,Gastaldi F,Vasile A,Fassino S. Duloxetine in obese binge eater outpatients: Preliminary results from a 12-week open trial. Hum Psychopharmacol 2009; 24: 483488.
  • 13
    Bernardi S,Pallanti S. Successful duloxetine treatment of a binge eating disorder: A case report. J Psychopharmacol 2008; 24: 12691272.
  • 14
    Lai CH. Duloxetine related binge eating behaviors: A case report. Prog Neuro-Psychopharmacol Biol Psychiatry 2009; 33: 15811582.
  • 15
    Christensen RC,Averbuch RN. The use of duloxetine in chronic bulimia nervosa: A case report. Psychiatry (Edgmont) 2009; 6: 2728.
  • 16
    Hazen E,Fava M. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: A case report. J Psychopharmacol 2006; 20: 723724.
  • 17
    Noma S,Uwatoko T,Yamamoto H,Hayashi T. Effects of milnacipran on binge eating—A pilot study. Neuropsychiatr Dis Treat 2008; 4: 295300.
  • 18
    El-Giamal N,de Zwaan M,Bailer U,Strnad A,Schussler P,Kasper S. Milnacipran in the treatment of bulimia nervosa: A report of 16 cases. Eur Neuropsychopharmacol 2003; 13: 7379.
  • 19
    Malhotra S,King KH,Welge JA,Brusman-Lovins L,McElroy SL. Venlafaxine treatment of binge-eating disorder associated withobesity: A series of 35 patients. J Clin Psychiatry 2002; 63: 802806.
  • 20
    FDA. Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events, 2010; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm198221.htm. Accessed 2010 February 8.
  • 21
    Appolinario JC,Bacaltchuk J,Sichieri R,Claudino AM,Godoy-Matos A,Morgan C, et al. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60: 11091116.
  • 22
    Milano W,Petrella C,Casella A,Capasso A,Carrino S,Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study. Adv Ther 2005; 22: 2531.
  • 23
    Wilfley DE,Crow SJ,Hudson JI,Mitchell JE,Berkowitz RI,Blakesley V, et al. Efficacy of sibutramine for the treatment of binge eating disorder: A randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008; 165: 5158.
  • 24
    Hudson JI,Wohlreich MM,Kajdasz DK,Mallinckrodt CH,Watkin JG,Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005; 20: 327341.
  • 25
    Rush AJ,Giles DE,Schlesser MA,Fulton CL,Weissenburger J,Burns C. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986; 18: 6587.
  • 26
    First M,Spitzer R,Gibbon M,Williams J. Structured Clinical Interview for DSM-IV-TR Axis I disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 2002.
  • 27
    Reas DL,Grilo CM,Masheb RM. Reliability of the Eating Disorder Examination-Questionnaire in patients with binge eating disorder. Behav Res Ther 2006; 44: 4351.
  • 28
    Guy W. ECDEU Assessment Manual for Psychopharmacology, U.S. Department of Health, Education, and Welfare publication (ADM). Rockville, MD: National Institute of Mental Health, 1976.
  • 29
    Goodman WK,Price LH,Rasmussen SA,Mazure C,Fleischmann RL,Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 10061011.
  • 30
    Stunkard AJ,Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985; 29: 7183.
  • 31
    Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 5055.
  • 32
    Fitzmaurice G,Laird NMWare JH. Applied Longitudinal Analysis. Hoboken, NJ: John Wiley & Sons, 2004, pp. 6072.
  • 33
    Gibbons RD,Hedeker D,Elkin I,Waternaux C,Kraemer HC,Greenhouse JB, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50: 739750.
  • 34
    McElroy SL,Casuto LS,Nelson EB,Lake KA,Soutullo CA,Keck PEJr,Hudson JI. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. Am J Psychiatry 2000; 157: 10041006.
  • 35
    Arnold LM,McElroy SL,Hudson JI,Welge JA,Bennett AJ,Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002; 63: 10281033.
  • 36
    McElroy SL,Hudson JI,Malhotra S,Welge JA,Nelson EB,Keck PEJr. Citalopram in the treatment of binge-eating disorder: A placebo-controlled trial. J Clin Psychiatry 2003; 64: 807813.
  • 37
    McElroy SL,Arnold LM,Shapira NA,Keck PEJr,Rosenthal NR,Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255261.
  • 38
    McElroy SL,Kotwal R,Guerdjikova AI,Welge JA,Nelson EB,Lake KA, et al. Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial. J Clin Psychiatry 2006; 67: 18971906.
  • 39
    McElroy SL,Guerdjikova A,Kotwal R,Welge JA,Nelson EB,Lake KA, et al. Atomoxetine in the treatment of binge-eating disorder: A randomized placebo-controlled trial. J Clin Psychiatry 2007; 68: 390398.
  • 40
    Guerdjikova AI,McElroy SL,Kotwal R,Welge JA,Nelson E,Lake K, et al. High-dose escitalopram in the treatment of binge-eating disorder with obesity: A placebo-controlled monotherapy trial. Hum Psychopharmacol 2008; 23: 111.
  • 41
    Guerdjikova AI,McElroy SL,Welge JA,Nelson E,Keck PE,Hudson JI. Lamotrigine in the treatment of binge-eating disorder with obesity: A randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009; 24: 150158.
  • 42
    Trivedi MH,Rush AJ,Ibrahim HM,Carmody TJ,Biggs MM,Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004; 34: 7382.
  • 43
    Perroud N,Relecom C,Huguelet P. Successful treatment of nicotine withdrawal with duloxetine: A case report. J Clin Psychopharmacol 2008; 28: 102104.
  • 44
    Ji D,Gilpin NW,Richardson HN,Rivier CL,Koob GF. Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19: 112.
  • 45
    Marcil WA,Petty F. Duloxetine associated with smoking cessation. Ann Pharmacother 2005; 39: 15781579.
  • 46
    Davis C,Carter JC. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite 2009; 53: 18.
  • 47
    Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007; 15: 481491.
  • 48
    Nestler EJ,Carlezon WAJr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 11511159.